Copenhagen, March 6, 2026, 11:09 CET
Zealand Pharma shares plunged Friday, dropping 32.53% to 249.10 Danish crowns by 10:40 a.m. local time. Investors punished the Danish biotech after fresh data on its obesity drug petrelintide disappointed, sending the stock toward a record single-day loss and slashing around 8.3 billion crowns ($1.3 billion) from its market cap.
This shift is significant: petrelintide is central to Zealand’s ambitions in obesity—and to Roche’s bid for a leading spot in the weight-loss drug race. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound currently dominate; both are GLP-1 drugs that suppress appetite via gut hormone action. Roche last year struck a deal valued at up to $5.3 billion for the rights to Zealand’s compound.
Zealand and Roche reported Thursday that petrelintide, their amylin analogue, led to as much as 10.7% weight loss in a Phase 2 trial involving 493 overweight or obese adults without type 2 diabetes, over a 42-week period. Placebo patients lost just 1.7%. The drug is intended to act like a naturally occurring hormone that signals satiety after eating.
Zealand kept the spotlight on tolerability. CEO Adam Steensberg argued the latest results move the company a step closer to obesity drugs that, as he put it, “fit the lives they actually want to live.” Chief Medical Officer David Kendall pointed to double-digit weight loss, underscoring what he called an “exceptional tolerability profile.” GlobeNewswire
All eyes on the benchmark: Eli Lilly’s amylin-based eloralintide posted up to 20.1% weight loss over 48 weeks in a similar mid-stage trial. Jefferies called petrelintide “2nd-best to Lilly’s elora for now.” The outcome, said KBC Securities, complicates any attempt at “first line positioning.” Reuters
The comparison isn’t straightforward. Morningstar’s Karen Andersen pointed out the challenge: women accounted for 53% of participants in Zealand’s trial, versus 78% in Lilly’s. Zealand also told analysts their female subjects posted roughly six percentage points more weight loss than men, after adjusting for placebo.
Zealand leaned hard on its data for side effects—specifically the stomach issues that frequently cause patients to quit obesity meds. Among those on the top dose, the company reported zero cases of vomiting, and not a single person dropped out due to gastrointestinal problems. On top of that, 98% hit the target maintenance dose.
The company plans to share more detailed data at a scientific meeting later this year. Phase 3 testing of petrelintide, handled in-house, is still slated to begin in the second half of 2026. A Phase 2 trial pairing petrelintide with Roche’s CT-388 is set to kick off in the first half.
The risk stands out. Should upcoming data or those Phase 3 results fall short—whether on weight loss, tolerability, or keeping patients on the drug—petrelintide could have a hard time competing with Lilly or the dominant GLP-1 crowd. For Zealand and Roche, there’s a lot riding on this; the partnership carries a potential $5.3 billion payday and forms a core plank of their obesity strategy.
Friday’s rout made clear: investors aren’t waiting around for obesity drug pipelines to mature. Novo Nordisk took a hit last month when its next-gen CagriSema lagged Lilly’s candidate in direct testing. Roche, for its part, is still gunning for a top-three market slot. Right now, though, Zealand’s data struck investors as a win for tolerability—not knockout weight loss.
